| 24.53 -2.56 (-9.45%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 34.81 | 1-year : | 43.19 |
| Resists | First : | 29.8 | Second : | 36.97 |
| Pivot price | 25.64  |
|||
| Supports | First : | 18.2 | Second : | 15.14 |
| MAs | MA(5) : | 27.89 |
MA(20) : | 24.49 |
| MA(100) : | 15.45 |
MA(250) : | 18.21 |
|
| MACD | MACD : | 1.5 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 57 |
D(3) : | 68 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 41.41 | Low : | 4.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CUE ] has closed above bottom band by 45.4%. Bollinger Bands are 24.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.98 - 29.21 | 29.21 - 29.37 |
| Low: | 22.8 - 23.02 | 23.02 - 23.16 |
| Close: | 24.69 - 25.04 | 25.04 - 25.28 |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
Thu, 11 Jun 2026
Cue Biopharma (CUE) VP and Principal Accounting Officer files initial Form 3 - Stock Titan
Thu, 11 Jun 2026
Ray Sumita reports Cue Biopharma (CUE) shares and 109,179-share option - Stock Titan
Tue, 09 Jun 2026
Cue Biopharma Company Profile & Introduction - Moomoo
Mon, 08 Jun 2026
Cue Biopharma (CUE) director awarded 1,626 stock options at $21.90 strike - Stock Titan
Mon, 08 Jun 2026
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Mon, 08 Jun 2026
Cue Biopharma, Inc. - MLQ.ai
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.61e+006 (%) |
| Held by Institutions | 8.5 (%) |
| Shares Short | 251 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.816e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -59.7 % |
| Operating Margin | -94.4 % |
| Return on Assets (ttm) | -46.1 % |
| Return on Equity (ttm) | -138.6 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 185 |
| Sales Per Share | 1.73861e+007 |
| EBITDA (p.s.) | -4.67089e+006 |
| Qtrly Earnings Growth | -4.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 255160 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|